tiprankstipranks
Optinose Inc (OPTN)
NASDAQ:OPTN

Optinose Stock Analysis & Ratings

OPTN Stock Chart & Stats

Day’s Range$1.85 - $1.98
52-Week Range$1.46 - $3.85
Previous Close$1.85
Volume16.51K
Average Volume (3M)308.05K
Market Cap$162.05M
P/E Ratio-1.2
Beta0.47
Next EarningsAug 16, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score3
EPS (TTM)-1.48


Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

OPTN FAQ

What was Optinose’s price range in the past 12 months?
Optinose lowest stock price was $1.46 and its highest was $3.85 in the past 12 months.
    What is Optinose’s market cap?
    Optinose’s market cap is $162.05M.
      What is Optinose’s price target?
      The average price target for Optinose is $6.00. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $6.00 ,the lowest forecast is $6.00. The average price target represents 206.12% Increase from the current price of $1.96.
        What do analysts say about Optinose?
        Optinose’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 1 Wall Streets Analysts.
          When is Optinose’s upcoming earnings report date?
          Optinose’s upcoming earnings report date is Aug 16, 2022 which is in 91 days.
            How were Optinose’s earnings last quarter?
            Optinose released its earnings results on May 12, 2022. The company reported -$0.31 earnings per share for the quarter, missing the consensus estimate of -$0.27 by -$0.04.
              Is Optinose overvalued?
              According to Wall Street analysts Optinose’s price is currently Undervalued.
                Does Optinose pay dividends?
                Optinose does not currently pay dividends.
                What is Optinose’s EPS estimate?
                Optinose’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Optinose have?
                Optinose has 82,680,000 shares outstanding.
                  What happened to Optinose’s price movement after its last earnings report?
                  Optinose reported an EPS of -$0.31 in its last earnings report, missing expectations of -$0.27. Following the earnings report the stock price went down -5.376%.
                    Which hedge fund is a major shareholder of Optinose?
                    Among the largest hedge funds holding Optinose’s share is GMT Capital Corp. It holds Optinose’s shares valued at 3M.

                      ---

                      Optinose Stock Analysis

                      Smart Score
                      3
                      Underperform
                      1
                      2
                      3
                      4
                      5
                      6
                      7
                      8
                      9
                      10
                      Price Target
                      $6.00
                      ▲(206.12% Upside)
                      Moderate Buy
                      The Optinose stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description

                      Optinose Inc

                      OptiNose, Inc. is a pharmaceutical company, which engages in the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists. Its products include the XHANCE and ONZETRA Xsail. The company was founded by Per Gisle Djupesland and Helena Kyttari Djupesland in October 2000 and is headquartered in Yardley, PA.

                      ---
                      Similar Stocks
                      Company
                      Price & Change
                      Follow
                      Rhythm Pharmaceuticals
                      OrthoPediatrics
                      Odonate Therapeutics
                      scPharmaceuticals
                      Deciphera Pharmaceuticals

                      Popular Stocks

                      ---
                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis